Green light for clinical trials of Nouscom's personalized cancer immunotherapy

NOUS-PEV is a personalized vaccine designed for each patient based on the selection and prioritization of mutations unique to that patient's tumour. The strategy is based on Nouscom's heterologous prime-boost platform underpinning its lead off-the-shelf clinical program NOUS-209, composed of a proprietary non-human adenoviral vector (GAd) and Modified Vaccinia Virus (MVA). Each of the two viral vector systems encodes multiple personalized neoantigens selected with a proprietary algorithm (VENUS), which prioritizes up to 60 mutations that represent the most immunogenic neoantigens.

Results from preclinical proof-of-concept studies (published in Nature Communications) demonstrated that a single administration of the GAd vaccine incorporating many neoantigens can eradicate large tumours when combined with checkpoint inhibition such as anti-PD1 or anti-PD-L1 treatment and triples the efficacy of such checkpoint inhibitors. The preclinical results also demonstrated strong and broad CD8+ and CD4+ neoantigen-specific T cell responses following vaccination, which are known to be indicative of a clinical anti-tumour effect.

The Spanish National Agency of Medicines and Medical Devices (Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) has given Nouscom a green light to launch phase 1 clinical trials of NOUS-PEV, as a potential treatment for patients with either locally advanced 1L melanoma or 1L non-small cell lung cancer (NSCLC).

The new Phase 1b trial will evaluate the safety, feasibility, and preliminary efficacy per RESIST 1.1 criteria of NOUS-PEV in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab in 28 patients with either locally advanced 1L melanoma or 1L NSCLC expressing more than 50% PD-L1. This multicenter trial will be conducted in Spain and other European countries.

Patricia Delaite, Chief Medical Officer of Nouscom, said: "We have generated exciting pre-clinical data, which demonstrated the ability of NOUS-PEV to present multiple cancer neoantigens to the immune system and promote potent and broad immune responses. The enhanced anti-tumour effects seen by combining NOUS-PEV with checkpoint inhibitors suggests these two approaches are highly synergistic and could potentially overcome tumour resistance to anti-PD1 immunotherapies to address a high unmet medical need. We look forward to starting this trial in the coming weeks and to generating results that we hope will confirm these exciting results in patients.”

(Press release)